Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Suheung Co., Ltd. (008490:KRX), powered by AI.
Suheung Co., Ltd. is currently trading at ₩19,340. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Suheung Co., Ltd. on Alpha Lenz.
Suheung Co., Ltd.'s P/E ratio is 5.1.
“Suheung Co., Ltd. trades at a P/E of 5.1 (undervalued) with solid ROE of 9.2%.”
Ask for details →Suheung Co., Ltd. is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and distribution of empty hard gelatin capsules. These capsules are crucial components of the pharmaceutical and nutraceutical sectors, serving as the primary shell for a variety of medicines and dietary supplements. With a focus on quality and innovation, Suheung emphasizes the production of capsules that cater to various formulation needs, including gelatin, HPMC (Hydroxypropyl methylcellulose) for vegetarians, and others geared towards specific pharmaceutical applications. The company’s operations have a significant impact on the healthcare and pharmaceutical industries, as its products are essential for drug delivery systems. Suheung Co., Ltd. holds a strong market position thanks to its commitment to technological advancements and meeting stringent quality standards. Its manufacturing processes and global distribution channels ensure a steady supply to major markets worldwide, underscoring its role as a reliable partner in the pharmaceutical supply chain. Established in South Korea, Suheung continues to expand its presence by continuously upgrading its manufacturing capabilities and adhering to international regulatory standards.
“Suheung Co., Ltd. trades at a P/E of 5.1 (undervalued) with solid ROE of 9.2%.”
Ask for details →Suheung Co., Ltd. (ticker: 008490) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 742 employees. Market cap is $223.7B.
The current price is ₩19,340 with a P/E ratio of 5.14x and P/B of 0.46x.
ROE is 9.22% and operating margin is 7.02%. Annual revenue is $722.3B.